Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378783 | 1.00 | TSHR (0.39) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL12378787 | 1.00 | TSHR (0.39) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL5592332 | 0.80 | TSHR (0.41) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL9360332 | 0.79 | TSHR (0.44) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL9467064 | 0.78 | TSHR (0.43) | TSHRRGS12MEN1KMT2A | |
| Threonine SCHEMBL11423702 | 0.76 | SLC7A5 (0.34) | TSHRRGS12 | |
| SCHEMBL23596518 | 0.74 | TSHR (0.48) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL16597503 | 0.74 | TSHR (0.48) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL98976 | 0.74 | TSHR (0.48) | TSHRRGS12MEN1KMT2A | |
| SCHEMBL14522121 | 0.74 | TSHR (0.40) | TSHRRGS12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | TSHR 4380/4885RGS12 2395/4885MEN1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.